cagrisema cagrilintide semaglutide phase 3 obesity is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had ≥1 weight-related complication, individuals assigned to a combination ACC 2026: Meta-analysis supports CagriSema
Description
NEJM 2025 (REDEFINE-2) Novo Nordisk FDA NDA submission announcement (December 18, 2025) Eli Lilly TRIUMPH-4 topline results (December 2025) Frequently Asked Questions Retatrutide produces higher weight loss at 28.7% versus CagriSema's 20.4%a difference of 21 pounds for a 250-pound person
Your liver plays a vital role in filtering toxins, breaking down fats, and keeping your body in balance
Its value is in what it adds when combined with GLP-1 agonism
The term lipotropic literally means fat-loving, referring to compounds that promote the transport, breakdown, and removal of fat from the liver
